Efficacy and safety of chimeric antigen receptor T-cells treatment in central nervous system lymphoma: a PRISMA-compliant single-arm meta-analysis

Lv, Liwei; Wu, Yuchen; Han, Song; Sun, Xin; Deng, Zixin; Huo, Hongjia; Li, Ruonan; Liu, Yuanbo

doi:10.1007/s00262-022-03246-w

Cited by 4 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, studies have demonstrated that the most common ICANS with CAR-T cells include encephalopathy, headache, tremor, dizziness, aphasia, delirium, insomnia, and anxiety (39,40). L. Lv et al (41)explored the safety of CAR-T cells for central nervous system lymphoma (CNSL). A total of 63 patients were included in 8 studies in the meta-analysis, and the incidence of grade 3 or above neurotoxicity was found to be 12%.…”

Section: Nervous System Toxicitiesmentioning

confidence: 99%

See 1 more Smart Citation

Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors

2022

View full text Add to dashboard Cite

Chimeric antigen receptor T (CAR-T) cells technology has been successfully used in the treatment of B cell-derived hematological tumors and multiple myeloma. CAR-T cells are also being studied in a variety of solid tumors. Current clinical reports on CAR-T cells in the treatment of malignant tumors are abundant. The tumor-killing activity of CAR-T cells and the unique adverse effects of CAR-T cells have been confirmed by many studies. There is evidence that serious adverse events can be life-threatening. CAR-T cells therapy is increasingly used in clinical settings, so it is important to pay attention to its serious adverse events. In this review, we summarized the serious adverse events of CAR-T cells in the treatment of malignant tumors by reading literature and searching relevant clinical studies, and discussed the management and treatment of serious adverse events in an effort to provide theoretical support for clinicians who deal with such patients.

show abstract

Section: Nervous System Toxicitiesmentioning

confidence: 99%

“…L. Lv et al. ( 41 )explored the safety of CAR-T cells for central nervous system lymphoma (CNSL). A total of 63 patients were included in 8 studies in the meta-analysis, and the incidence of grade 3 or above neurotoxicity was found to be 12%.…”

Section: Clinical Presentation Of Saes Associated With Car-t Cells Th...mentioning

confidence: 99%

Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors

2022

View full text Add to dashboard Cite

show abstract

Clinical outcomes of chimeric antigen receptor T-cell therapy following autologous hematopoietic stem cell transplantation in 38 patients with refractory/relapsed primary or secondary central nervous system lymphoma

Wu,

Liu,

Cao

et al. 2024

Cancer Immunol Immunother

View full text Add to dashboard Cite

Background Several reports have indicated that chimeric antigen receptor (CAR) T-cell therapy following autologous hematopoietic stem cell transplantation (ASCT) is a promising strategy for refractory/relapsed (r/r) central nervous system lymphoma (CNSL), but the number of reported cases is limited. Methods The cohort in this retrospective study consisted of 38 patients with r/r CNSL who received CAR T-cell therapy following ASCT at our center between January 2019 and April 2024. Group comparisons of continuous variables were tested using the unpaired Student’s t-test or the Mann–Whitney U-test, while categorical variables were analyzed using Fisher's exact test. The Kaplan–Meier method was employed to estimate survival curves, and group comparisons were performed using the log-rank test. Results The cohort comprised 38 patients with r/r CNSL, all of whom had active CNS involvement. After therapy, the best overall response rate (ORR) of all patients was 78.9%. Subgroup analysis found that a lower ORR was observed in patients with lactate dehydrogenase levels above the upper limit of normal (60.0% vs. 91.3%, P = 0.039). With a median follow-up of 37.5 months, the estimated 1-year overall survival (OS) and progression-free survival (PFS) rates were 72.8% and 57.4%, respectively. The risk factors associated with PFS was no response to current therapy (adjusted hazard ratio: 22.87, P < 0.001). The incidence rates of severe cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome were both 13.2%. Among the 25 patients with secondary CNSL (SCNSL), the best ORRs were 91.7% for those with CNS lesions only and 61.5% for those with CNS and systemic lesions ( P = 0.160), while the estimated 1-year PFS rates were 83.3% and 38.5%, respectively ( P = 0.030). Conclusions CAR T-cell therapy following ASCT shows promising efficacy for r/r CNSL patients. Besides, SCNSL patients with CNS and systemic lesions have inferior treatment efficacy compared to those with CNS lesions only. Electronic supplementary material The online version of this article (10.1007/s00262-024-03855-7) contains supplementary material, which is available to authorized users.

show abstract

Novel Therapies for Primary Central Nervous System Lymphomas

Aquilanti,

Herrity,

Nayak

2024

Curr Neurol Neurosci Rep

View full text Add to dashboard Cite

Efficacy and safety of chimeric antigen receptor T-cells treatment in central nervous system lymphoma: a PRISMA-compliant single-arm meta-analysis

Cited by 4 publications

References 35 publications

Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors

Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors

Clinical outcomes of chimeric antigen receptor T-cell therapy following autologous hematopoietic stem cell transplantation in 38 patients with refractory/relapsed primary or secondary central nervous system lymphoma

Novel Therapies for Primary Central Nervous System Lymphomas

Contact Info

Product

Resources

About